文献速递流行病学与生物统计临床试验与 GCP

2型糖尿病药物治疗的获益与危害:随机对照试验的系统综述与网状Meta分析

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
PubMed 文献 · BMJ · 2023-04-06

该系统综述与网状Meta分析纳入截至2022年10月14日的816项随机对照试验、共471 038例2型糖尿病成人患者,评估13类降糖药物的获益与危害。与标准治疗相比,SGLT-2抑制剂和GLP-1受体激动剂降低全因死亡(OR均为0.88),非甾体类盐皮质激素受体拮抗剂(仅非奈利酮在慢性肾病患者中测试)可能降低死亡(OR 0.89)。替尔泊肽可能带来最大体重降幅(平均差-8.57 kg)。

要点

  • SGLT-2抑制剂与GLP-1受体激动剂降低全因死亡(OR 0.88,高确信度)。
  • 非奈利酮可能降低死亡(OR 0.89)、因心衰住院和终末期肾病,可能降低心血管死亡。
  • 替尔泊肽可能带来最大体重降幅(平均差-8.57 kg),但严重胃肠道不良事件与其及GLP-1受体激动剂相关。

核心结论

  • 该网状Meta分析在确认SGLT-2抑制剂和GLP-1受体激动剂对心血管、肾脏结局及死亡有实质性获益的基础上,补充了非奈利酮和替尔泊肽的信息。
  • 这些发现突出表明需要持续评估科学进展,以便在2型糖尿病临床实践指南中引入前沿更新。

研究设计与样本

  • 系统综述与网状Meta分析,检索Ovid Medline、Embase和Cochrane Central至2022年10月14日。
  • 纳入成人2型糖尿病、随访24周或更长的随机对照试验,排除系统比较一种以上药物类别联合与无药比较的试验、随机对照试验的亚组分析及非英语研究。
  • 共纳入816项试验、471 038例患者,评估13种不同药物类别;所有后续估计均指与标准治疗的比较。
  • 采用GRADE方法评估证据确信度。

主要发现

  • SGLT-2抑制剂(OR 0.88,95%CI 0.83至0.94;高确信度)和GLP-1受体激动剂(OR 0.88,95%CI 0.82至0.93;高确信度)降低全因死亡。
  • 非甾体类盐皮质激素受体拮抗剂(迄今仅在慢性肾病患者中测试非奈利酮)可能降低死亡(OR 0.89,95%CI 0.79至1.00;中等确信度);其他药物可能不降低死亡。
  • SGLT-2抑制剂和GLP-1受体激动剂降低心血管死亡、非致死性心肌梗死、因心衰住院和终末期肾病;非奈利酮可能降低因心衰住院和终末期肾病,并可能降低心血管死亡。
  • 仅GLP-1受体激动剂降低非致死性卒中;SGLT-2抑制剂在降低终末期肾病方面优于其他药物;GLP-1受体激动剂以及可能SGLT-2抑制剂和替尔泊肽改善生活质量。
  • 替尔泊肽可能带来最大体重降幅(平均差-8.57 kg;中等确信度);基础胰岛素(平均差2.15 kg;中等确信度)和噻唑烷二酮类(平均差2.81 kg;中等确信度)可能带来最大体重增幅。

关键数值与推荐

  • 报告的危害 largely 为药物类别特异性,例如SGLT-2抑制剂的生殖器感染、替尔泊肽和GLP-1受体激动剂的严重胃肠道不良事件、非奈利酮导致住院的高钾血症。
  • SGLT-2抑制剂、GLP-1受体激动剂和非奈利酮的绝对获益因2型糖尿病患者的基线心血管和肾脏风险而异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Ovid Medline, Embase, and Cochrane Central up to 14 October 2022. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach. RESULTS: The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and end stage kidney disease, and possibly cardiovascular death. Only GLP-1 receptor agonists reduce non-fatal stroke; SGLT-2 inhibitors are superior to other drugs in reducing end stage kidney disease. GLP-1 receptor agonists and probably SGLT-2 inhibitors and tirzepatide improve quality of life. Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events with tirzepatide and GLP-1 receptor agonists, hyperkalaemia leading to admission to hospital with finerenone). Tirzepatide probably results in the largest reduction in body weight (mean difference -8.57 kg; moderate certainty). Basal insulin (mean difference 2.15 kg; moderate certainty) and thiazolidinediones (mean difference 2.81 kg; moderate certainty) probably result in the largest increases in body weight. Absolute benefits of SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone vary in people with type 2 diabetes, depending on baseline risks for cardiovascular and kidney outcomes (https://matchit.magicevidence.org/230125dist-diabetes). CONCLUSIONS: This network meta-analysis extends knowledge beyond confirming the substantial benefits with the use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing adverse cardiovascular and kidney outcomes and death by adding information on finerenone and tirzepatide. These findings highlight the need for continuous assessment of scientific progress to introduce cutting edge updates in clinical practice guidelines for people with type 2 diabetes. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022325948.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023. PMID: 37024129. doi:10.1136/bmj-2022-074068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。